ImmuPharma (LON:IMM) Trading 56.4% Higher – Here’s Why

ImmuPharma plc (LON:IMM)’s stock price traded up 56.4% during mid-day trading on Tuesday . The stock traded as high as GBX 8.70 ($0.12) and last traded at GBX 8.06 ($0.11). 44,629,688 shares traded hands during mid-day trading, an increase of 509% from the average session volume of 7,327,748 shares. The stock had previously closed at GBX 5.16 ($0.07).

ImmuPharma Stock Up 20.3%

The firm’s 50-day moving average is GBX 2.72 and its 200-day moving average is GBX 2.82. The company has a market capitalization of £64.94 million, a PE ratio of -1,460.11 and a beta of 1.53.

ImmuPharma (LON:IMM) last posted its quarterly earnings results on Wednesday, August 6th. The company reported GBX (0.38) EPS for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. As a group, equities research analysts predict that ImmuPharma plc will post -339.0000022 EPS for the current year.

About ImmuPharma

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.